Skip to main content

Ovarian Cancer

No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer

PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy

Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis

Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer

Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer

Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation

Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer

Long-Term Responders to Rucaparib More Likely to Have Deleterious BRCA Mutations

Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer

Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer

6
7
8
9
10
11
12

Page 9 of 13
Results 81 - 90 of 125